@entity567 -based immunotherapy against XXXX 9L @entity11 .

@entity3692 @entity1313 @entity5 @entity1221 @entity11 @entity567 @entity56 @entity35
OBJECTIVE: @entity567 ( @entity567 ) may be useful for immunotherapy against @entity11 because it can reverse the @entity11 -induced suppression of T-cell proliferation and @entity3692 production. We postulated that peripheral infusion of @entity567 along with irradiated @entity5 cells can lead to immunological rejection of 9L @entity11 . METHODS: 9L @entity5 were established in syngeneic Fischer 344 @entity35 . Osmotic minipumps delivered @entity567 subcutaneously, and irradiated 9L cells were injected on Days 0, 3, 7, 14, and 21. @entity5 volumes were measured by a blinded observer. For @entity5 rechallenge, animals initially cured of 9L @entity5 received either another @entity5 or a stereotactic injection of 10(6) 9L cells into the right striatum. @entity56 was measured after injecting 10(6) irradiated 9L @entity5 cells into the right pinnae. RESULTS: @entity5 growth curves were significantly different between treated and control animals. Among the animals that received 1 ng per day of @entity567 , 40% did not develop any measurable @entity5 at all. A combination of irradiated 9L cells and @entity567 was necessary for optimal effect. Cured animals rejected @entity5 . All animals rechallenged with intraparenchymal @entity1313 survived, whereas control animals all died by Day 22. @entity56 measurements showed a specific and long-lasting response against 9L cells. CONCLUSION: Continuous administration of the lymphokine @entity567 , in the presence of irradiated @entity5 cells for antigen presentation, circumvents the need for gene transfection for generating @entity5 cell vaccines. We have demonstrated that the combination of @entity567 and irradiated @entity5 cells can lead to regression of 9L @entity5 and resistance to future @entity1221 challenges.
